Claritev
NYSE: CTEV
$21.66 ▼ -1.61  (-6.92%)
At close: Jul 24, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap412.35 Mn
P/E-1.35
P/S0.42
Div. Yield0.00
ROIC (Qtr)0.00
Total Debt (Qtr)4.59 Bn
Revenue Growth (1y) (Qtr)5.77
Add ratio to table…

About

Claritev Corporation is a technology data and insights company focused on improving transparency affordability and quality across the healthcare system. The company applies data analytics and artificial intelligence to help payers employers and providers understand costs pricing and payment dynamics. Founded in 1980 Claritev draws on over 45 years of claims experience to deliver solutions that reduce medical cost burdens and support fair reimbursements. The company’s…

Read more ↓
Sector: Healthcare Industry: Health Information Services CIK: 0001793229

Investment Thesis

▲ Bull case
  • Claritev is positioned to capitalize on a structural shift toward AI-driven operational efficiency that management underemphasized during the Q&A, where they revealed internal engineering teams are nearly doubling coding capacity without headcount growth through widespread AI tool adoption—a metric not reflected in reported financials but signaling substantial margin expansion potential as these productivity gains scale across sales, finance, and client-facing workflows beyond the highlighted claims intelligence examples. This hidden catalyst addresses investor skepticism about AI ROI in regulated industries by demonstrating tangible internal efficiency improvements that directly support their long-term deleveraging goals while maintaining adjusted EBITDA margins in the 60%+ range, creating a pathway to exceed the $1 billion revenue target through self-funded innovation rather than dilutive investment.
  • The company's expansion into the TPA market via PHCS Novera represents an underappreciated growth vector that aligns with unspoken pressures from employers demanding cost-control solutions amid projected 9.5% healthcare cost inflation in 2026—a trend management noted but did not quantify in terms of addressable market size or timing of revenue contribution, despite Dallas Scrip's hire signaling serious commitment to this vertical; with TPAs managing nearly two-thirds of self-funded plans, Claritev's ability to bundle regional network depth with national access through solutions like PHCS Novera taps into a durable structural shift away from monolithic payer networks, creating recurring revenue opportunities that complement their core PSAV business where growth is already shifting toward higher-acuity, complex claims less vulnerable to utilization fluctuations.
  • Claritev's strategic focus on converting ACV to revenue exhibits de-risked execution visibility that the market overlooks, as evidenced by Q1 bookings showing 73% from cross-sell/upsell to existing clients—a mix indicating lower customer acquisition cost and faster revenue recognition compared to pure new logo hunting—while management disclosed a pipeline coverage ratio of 4.8x quota (up from 1.5x two years prior) without elaborating on how this dramatically improves forecast accuracy for the $80-$100M ACV target, reducing the perceived risk of execution delays in their growth initiatives and supporting confidence in achieving the 3-5% second-half revenue acceleration guided for FY26.
▼ Bear case
  • Claritev faces significant headwinds from its unsustainable capital structure that management consistently avoids addressing directly, as highlighted by the Q1 cash flow statement showing $129.3 million in interest paid versus only $36.8 million of unlevered free cash flow—a coverage ratio of just 0.28x that necessitates aggressive revolver borrowing ($145 million drawn in Q1) to service debt, with long-term debt at $4.57 trillion creating a refinancing cliff risk that contradicts their Vision 2030 narrative and forces allocation of cash flow to interest rather than growth investments or deleveraging, a structural vulnerability exposed when Doug Garis acknowledged Q1 and Q3 are expected cash consumption quarters due to the debt schedule.
  • The company's reliance on PSAV revenue presents a hidden vulnerability masked by favorable rate mix trends, as management admitted to modest volume declines in Q1 that were offset by higher-acuity claims—a dynamic that may not persist if employer cost-containment pressures intensify under Medicare Advantage rate scrutiny, which Travis Dalton dismissed as having "limited impact" on volumes despite Stan Berenshteyn's question about payment integrity demand growth, revealing a potential disconnect between management's optimism and actual payer behavior shifts toward reducing utilization that could undermine the core business where 80% of identified savings historically derive from outpatient higher-acuity areas.
  • Claritev's services expansion strategy carries unacknowledged execution risks that management glossed over when discussing the OPCG acquisition and top 5 health system win, as Doug Garis conceded service line margins are expected to be "roughly half the core business" while revealing only 20% of Q1 bookings came from provider/public sector verticals—indicating these strategic initiatives are currently contributing minimally to overall profitability despite requiring significant incremental investment ($20-$25M annualized), with Jessica Tassan's question about service margin progression left unanswered beyond vague assurances of recurrence, suggesting the market may be overestimating the near-term profitability and scalability of these newer offerings relative to the core network and payment integrity businesses.

Contract Type Breakdown of Revenue (2025)

Contract Type Breakdown of Revenue (2025)

Peer Comparison

Companies in the Health Information Services
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 VEEV Veeva Systems Inc 29.34 Bn31.168.84-
2 BTSG BrightSpring Health Services, Inc. 13.49 Bn46.180.992.50 Bn
3 HQY Healthequity, Inc. 7.96 Bn34.515.950.94 Bn
4 TXG 10x Genomics, Inc. 6.17 Bn-272.149.65-
5 HNGE Hinge Health, Inc. 6.02 Bn-11.779.31-
6 MMED MiniMed Group, Inc. 4.19 Bn-8.881.38-
7 WAY Waystar Holding Corp. 4.14 Bn32.803.581.47 Bn
8 DOCS Doximity, Inc. 3.82 Bn19.515.93-